The pharmaceutical industry wants future negotiations on drug pricing to include the extent to which drugs prevent costly hospital stays and details of other societal benefits they generate.
Aidan Lynch, general manager of GSK and president of the Irish Pharmaceutical Healthcare Association (IPHA), which represents the industry, said: “If we could look, not just at price in isolation, but at an end-to-end cost, such as bed days and reduced staff required – that type of...
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Get a Business Account for you and your team